2. Membrane Transporter/Ion Channel Neuronal Signaling
  3. GABA Receptor
  4. Rilmazafone

Rilmazafone (450191S) is an orally active sleep inducer. Rilmazafone targets cytochrome P-450b and cytochrome P-450e. Rilmazafone induces hepatic drug-metabolizing enzyme activity in rats, mice and dogs. Rilmazafone is applicable for insomnia-related research.

At equivalent molar concentrations, both the salt and free forms of a compound exhibit comparable biological activity. Nevertheless, the salt form (Rilmazafone hydrochloride) usually boasts enhanced water solubility and stability.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Rilmazafone

Rilmazafone Chemische Struktur

CAS. Nr. : 99593-25-6

Größe Verfügbarkeit
50 mg   Angebot einholen  
100 mg   Angebot einholen  
250 mg   Angebot einholen  

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

This product is a controlled substance and not for sale in your territory.

Other In-stock Forms of Rilmazafone:

Other Forms of Rilmazafone:

Rilmazafone Related Antibodies

Top Publications Citing Use of Products

  • Biologische Aktivität

  • Reinheit & Dokumentation

  • Verweise

  • Kundenbewertung

Beschreibung

Rilmazafone (450191S) is an orally active sleep inducer. Rilmazafone targets cytochrome P-450b and cytochrome P-450e. Rilmazafone induces hepatic drug-metabolizing enzyme activity in rats, mice and dogs. Rilmazafone is applicable for insomnia-related research[1][2].

In Vivo

Rilmazafone (450191S) (200-600 mg/kg; p.o.; daily for 3-5 days; single dose) pretreatment of rats induces hepatic cytochrome P-450-dependent drug-metabolizing enzymes, which reduces plasma concentrations of Rilmazafone metabolites, while a single high dose transiently suppresses specific hepatic enzyme activity[1].
Rilmazafone (450191S) (0.3-3 mg/kg; p.o.; single dose) exerts dose-dependent hypnotic effects in sleep-disturbed male Wistar rats, with significant sleep latency reduction at 1 and 3 mg/kg, significant awake time reduction and non-REM sleep time increase at 3 mg/kg, and significant reductions in non-REM sleep delta activity at 1 and 3 mg/kg, while leaving REM sleep time unchanged at all tested doses[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Jcl Sprague-Dawley (adult male, 7-8 weeks old)[1]
Dosage: 200 mg/kg (5-day pretreatment + single dose); 600 mg/kg (3-day pretreatment + 200 mg/kg single dose); 200 mg/kg (single dose, liver collection); 600 mg/kg (3-day pretreatment)
Administration: p.o.; daily for 3 days; daily for 5 days; single dose
Result: Showed plasma levels of metabolite M-1 similar to controls at peak but undetectable by 4 hours post-dose, M-2 plus M-D peaked at 2 hours then decreased rapidly, and M-3 plus M-A peaked between 2-4 hours then decreased rapidly in rats pretreated with 200 mg/kg daily for 5 days followed by 200 mg/kg single dose.
Showed peak plasma levels of all measured metabolites (M-1, M-2 plus M-D, M-3 plus M-A) significantly lower than controls, with M-1 peaking at 15-60 minutes, M-2 plus M-D peaking at 1 hour, and M-3 plus M-A peaking at 2 hours, all declining rapidly thereafter in rats pretreated with 600 mg/kg daily for 3 days followed by 200 mg/kg single dose.
Suppressed hepatic 7-methoxycoumarin O-demethylase activity to 45.1 nmol/min/g liver, a statistically significant reduction compared to controls in rats given a single 200 mg/kg dose with liver collection at 6 hours.
Increased hepatic 7-methoxycoumarin O-demethylase activity to 130.7 nmol/min/g liver, 7-ethoxycoumarin O-deethylase activity to 220.8 nmol/min/g liver, and 7-propoxycoumarin O-depropylase activity to 175.7 nmol/min/g liver, all statistically significant increases compared to controls in rats given 600 mg/kg daily for 3 days.
Animal Model: Wistar rats (male, 240-320 g, sleep disturbance model)[2]
Dosage: 0.3, 1, 3 mg/kg
Administration: p.o.; single dose
Result: Shortened sleep latency to 51.6 min (1 mg/kg) and 48.0 min (3 mg/kg), respectively, compared to control.
Decreased awake time to 198.0 min and increased non-REM sleep time to 139.0 min at 3 mg/kg compared to control.
Showed no significant effects on sleep latency, awake time, or non-REM sleep time at 0.3 mg/kg compared to control.
Caused no significant effects on total REM sleep time at all tested doses compared to control.
Molekulargewicht

475.33

Formel

C21H20Cl2N6O3
CAS. Nr.
SMILES

NCC(NCC1=NC(C(N(C)C)=O)=NN1C2=C(C=C(Cl)C=C2)C(C3=C(C=CC=C3)Cl)=O)=O
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
Verweise
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Rilmazafone Related Classifications

  • Molaritätsrechner

  • Verdünnungsrechner

Die Formel zur Berechnung von Molaritäten

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)

Diese Gleichung wird häufig abgekürzt als: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Rilmazafone99593-25-6GABA ReceptorGamma-aminobutyric acid Receptorγ-Aminobutyric acid Receptordogsrat liverinsomniahepatic drug-metabolizing enzymeCytochrome P-450bdelta activitynon-REM sleepratsCytochrome P-450emiceInhibitorinhibitorinhibit

Ihre kürzlich angesehenen Produkte:

Online-Anfrage

Your information is safe with us. * Required Fields.

Produktname

  

Requested Quantity *

Name des Antragstellers *

 

Anrede

E-Mail-Addresse *

 

Telefonnummer *

Department

 

Name der Organisation *

City

Bundesland

Country or Region *

      

Bemerkungen

Massenanfrage

Inquiry Information

Produktname:
Rilmazafone
Art. -Nr.:
HY-106547
Menge:
MCE Japan Authorized Agent:

Kundenbewertung

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Produktname

  

Lot #

Name des Antragstellers *

 

E-Mail-Addresse *

Telefonnummer

 

Department *

Name der Organisation *

 

Country or Region *

Bemerkungen

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.